Ovid Therapeutics (OVID) Q3 2024 Earnings
OVID·Reported November 12, 2024·Before market open
Ovid Therapeutics reported Q3 2024 revenue of $173.0K, missed analyst consensus of $187.5K by $14.5K. Diluted EPS came in at $-0.20, missed the $-0.19 consensus by $0.01.
Revenue
$173.0Kmissed by $14.5K
Consensus: $187.5KDiluted EPS
$-0.20missed by $0.01
Consensus: $-0.19
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Ovid Therapeutics's Q3 2024 earnings report.
Ovid Therapeutics (OVID) reported Q3 2024 earnings on November 12, 2024 before market open.
Ovid Therapeutics reported revenue of $173.0K and diluted EPS of $-0.20 for Q3 2024.
Revenue missed the consensus estimate of $187.5K by $14.5K. EPS missed the consensus estimate of $-0.19 by $0.01.
You can read the 10-Q periodic report (0001628280-24-046868) directly on SEC EDGAR. The filing index links above go to sec.gov.